Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOREY: Evolocumab and Atorvastatin Lipoprotein Kinetics
NCT02189837Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2014
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in primary hyperlipidemia and mixed dyslipidemia (4 arms), sponsored by Amgen. Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) at Day 50. Started Jul 2014; status: completed.
02
Drugs
evolocumab
03
Conditions
primary hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT02189837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189837.